

Luxembourg, 24.09.2019

Public

Environmental and Social Data Sheet

Overview

Project Name: MOLMED (EGFF)
Project Number: 2019-0151
Country: Italy
Project Description: The Project will finance the RDI activities of the Promoter to develop innovative anti-cancer and rare diseases treatments in the field of cell and gene therapy, during the investment period 2019-2022.

EIA required: no

Project included in Carbon Footprint Exercise¹: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Environmental and Social Assessment

Environmental Assessment

The Promoter's investments that will be financed through this operation concern research, development and innovation activities carried out in the pharmaceutical sector, more specifically in the cell and gene therapy field, enabling the Company to advance its promising platform for CAR-T² therapies, for treating haematological and solid tumours and other rare diseases.

The Project activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU, and are considered environmentally not harmful. Moreover, the Project will be carried out in existing facilities already authorised for similar activities and volumes.

The Promoter's RDI practices are in compliance with relevant national and EU regulations (directives 2001/20/EC and 2005/28/EC, as applicable) and the Promoter maintains adequate internal procedures and management practices. The Promoter's manufacturing facilities have been designed applying the highest standards in the field of gene therapy, in compliance with Good Manufacturing Practices guidelines.

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.

² Chimeric Antigen Receptor T-cells, receptor proteins that have been engineered to give T cells the new ability to target specific proteins, notably used in cancer therapies.

Luxembourg, 24.09.2019

Social Assessment, where applicable

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel therapies for diseases associated with substantial social and economic impact. The Company's development will allow maintaining and / or further enhancing European competencies and skills in an area of strategic importance for Europe, i.e. gene therapy.

Conclusions and Recommendations

If successful, the project presents potentially high health and societal benefits for the wider society. Considering the above, the project is deemed acceptable for the Bank's financing under environmental and social terms.

PJ/SQM/ECSO 24.09.2019